AUTHOR=Lee Chia-Chen , Te-Wei Kuan David , Chang Kai-Chun , Chen Zheng-Wei , Cheng Jen-Fang , Lin Ting-Tse , Lin Lian-Yu , Wu Cho-Kai 

TITLE=Comparative analysis of mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor in heart failure with mildly reduced ejection fraction

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1507326

DOI=10.3389/fphar.2024.1507326

ISSN=1663-9812

ABSTRACT=Figure : 3 0.78-1.02) or HHF (hazard ratio = 1.01, 95% CI: 0.94-1.09). Conversely, RASI//ARNI use was linked to a lower risk of cardiovascular death (hazard ratio = 0.82, 95% CI: 0.71-0.94) but not HHF (hazard ratio = 0.995, 95% CI: 0.924-1.07).Landmark analysis showed no significant difference in outcomes for follow-up durations exceeding two years.MRA had a neutral effect on cardiovascular death and HHF, while RASI/ARNI was associated with a lower risk of cardiovascular death. RASI/ARNI may be more beneficial than MRA for HFmrEF patients. Regular re-evaluation is essential to adjust heart failure treatment.